Poster: Neuregulin-1 treatment affects GABA and glutamate release after PCP co-treatment in freely moving mice.
Poster at the annual meeting of the Society for Neuroscience (SfN) 2013, San Diego (USA) Martin Engel, Andrew Jenner, Xu-Feng...
Poster: Neuregulin-1 application reduces PCP-induced hyperlocomotion and GABA release – potential implications for schizophrenia treatment
Poster at the annual meeting of the European Brain and Behaviour Society (EBBS) 2013, Munich (Germany) Martin Engel, Xu-Feng Huang,...
Paper: Neuregulin-1 signalling and antipsychotic treatment : Potential therapeutic targets in a schizophrenia candidate signalling pathway
First published review on the direction of our work and its relevance to patients with schizophrenia Deng, Chao, Bo Pan,...
QUANTITATION OF NEUROTRANSMITTERS AND METABOLITES IN MICRODIALYSATE FLUID AND BRAIN USING ADVANCED GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS)
Annual meeting of the Australian Neuroscience Society 2013, Melbourne (Australia) Martin Engel, Elisabeth Frank, Andrew Jenner
Peripheral Neuregulin-1 administration suppresses PCP-induced hyperlocomotion in adult mice
Annual meeting Biological Psychiatry Australia 2012, Melbourne (Australia) Martin Engel, Xu-Feng Huang, Elisabeth Frank
PCP-induced hyperlocomotion reduced by intracerebral Neuregulin-1 application in adult mice
Biannual meeting of the Federation of European Neuroscience Societies (FENS) 2012, Barcelona (Spain) Martin Engel, Xu-Feng Huang, Elisabeth Frank
NRG1 and Schizophrenia Treatment
ANS 2012 Oral Presentation Presented at: Annual Meeting of the Australian Neuroscience Society 2012, Gold Coast , Australia. Please read...